Copanlisib
 | |
| Names | |
|---|---|
| IUPAC name
2-Amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide | |
| Other names
BAY 80-6946 | |
| Identifiers | |
| 1032568-63-0 | |
| ChEMBL | ChEMBL3218576 |
| ChemSpider | 25069683 |
| Jmol interactive 3D | Image |
| MeSH | 2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo(1,2-c)quinazolin-4-yl)pyrimidine-5-carboxamide |
| UNII | WI6V529FZ9 |
| |
| |
| Properties | |
| C23H28N8O4 | |
| Molar mass | 480.53 g·mol−1 |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Copanlisib (BAY 80-6946), developed by Bayer, is a selective Class I phosphoinositide 3-kinase inhibitor[1] which has shown promise in Phase I/II clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia.[2]
References
- ↑ "Phase II Data of Bayer’s Novel Cancer Drug Candidate Copanlisib to be Presented". Retrieved 3 March 2015.
- ↑ Loguidice, Christina (8 December 2014). "Copanlisib Continues to Show Promise for Treating Indolent Lymphomas". Rare Disease Report. Retrieved 3 March 2015.
This article is issued from Wikipedia - version of the Monday, November 30, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.